Serology – ELISA

Chlamydia Trachomatis IgM – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies specific to Chlamydia trachomatis in human plasma and sera. The kit is intended for the follow up of patients undergoing a Chlamydia trachomatis infection. Micro-plates are coated with an immunodominant species-specific polypeptide derived from Chlamydia trachomatis major outer-membrane antigen (MOMP), that makes the assay very specific for C.trachomatis (no cross reaction with C.pneumoniae).In the 1st incubation, the solid phase is treated with diluted samples and anti-C.trachomatis IgG are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-C.trachomatis IgG are detected by the addition of anti hIgG antibody, labelled with peroxidase (HRP).The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-C.trachomatis IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (Uarb/ml) as no international standard is available.

Chlamydia Trachomatis IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies specific to Chlamydia trachomatis in human plasma and sera. The kit is intended for the follow up of patients undergoing a Chlamydia trachomatis infection. Micro-plates are coated with an immunodominant species-specific polypeptide derived from Chlamydia trachomatis major outer-membrane antigen (MOMP), that makes the assay very specific for C.trachomatis (no cross reaction with C.pneumoniae).In the 1st incubation, the solid phase is treated with diluted samples and anti-C.trachomatis IgG are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-C.trachomatis IgG are detected by the addition of anti hIgG antibody, labelled with peroxidase (HRP).The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-C.trachomatis IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (Uarb/ml) as no international standard is available.

Chlamydia Trachomatis IgA – ELISA

Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgA antibodies to Chlamydia Trachomatis in human plasma and sera. The product is intended for the follow-up of patients showing pathologies referable to Chl. Trachomatis infection. Micro-plates are coated with a species-specific polypeptide derived from C.trachomatis major outer membrane antigen. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.trachomatis IgA are captured, if present, by the antigens. After washing out all the other components of the sample, in the 2nd incubation bound anti-C.trachomatis IgA are detected by the addition of anti hIgA antibody, labelled with peroxidase (HRP).

Chlamydia Pneumoniae IgM – ELISA

Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Chlamydia Pneumoniae in human plasma and sera. The product is intended for the follow-up of patients showing respiratory pathologies referable to Chl. pneumoniae infection. Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgM are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-CP IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-CP IgM antibodies present in the sample. The presence of IgM in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples.Neutralization of IgG anti-CP, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.

Chlamydia Pneumoniae IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies to Chlamydia pneumoniae in human plasma and sera. The kit is intended for the follow up of patients undergoing a Chlamydia pneumoniae infection. Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgG are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-C.pneumoniae IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-C.pneumoniae IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (Uarb/ml) as no international standard is available.

Chlamydia Pneumoniae IgA – ELISA

Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgA antibodies to Chlamydia Pneumoniae in human plasma and sera. The product is intended for the follow-up of patients showing respiratory pathologies referable to Chl. Pneumoniae infection. Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgA are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-CP IgA are detected by the addition of anti hIgA antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-CP IgA antibodies present in the sample. The presence of IgA in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples. Neutralization of IgG anti-CP, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgA.

Syphilis IgM – ELISA

Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Treponema pallidum (Tp) in human plasma and sera. The kit is intended for the follow-up of Tp-infected patients. For "in vitro" diagnostic use only. Microplates are coated with Tp immunodominant synthetic antigens (recombinant p47, p17 and TmpA).In the 1st incubation, the solid phase is treated with diluted samples and anti-Tp IgM are captured, if present, by the antigens. After washing out all the other components of the sample, in the 2nd incubation bound anti-Tp IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-Tp IgM antibodies present in the sample. The presence of IgM in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples. Neutralization of IgG anti-Tp, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.

Meningitis IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the determination of IgG antibodies to groups ACWY Meningococcus in human plasma and sera. The product is intended for the follow-up of patients administered with a meningococcal vaccine, containing the polysaccharides from groups A, C, Y and W135. Micro-plates are coated with a preparation of purified capsular polysaccharides formed by serogroups A, B, C, Y and W135. In the 1st incubation, the solid phase is treated with diluted samples and anti-Meningococcus IgG are captured, if present, by the antigens.After washing out all the other components of the sample, in the 2nd incubation bound anti-Men IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-Men IgG antibodies present in the sample. A cut-off value permits to transform the optical density values detected in positive or negative results due to the presence of absence of anti-Men IgG.

Measles virus IgM – ELISA

Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgM antibodies to Measles Virus in human plasma and sera. The product is intended mostly for the identification of the pathogen in patients undergoing an exanthematic infection. Micro-plates are coated with Measles Virus native antigens derived from tissue culture of a virulent strain. In the 1st incubation, the solid phase is treated with diluted samples and anti Measles Virus IgM are captured, if present, by the antigens.After washing out all the other components of the sample, in the 2nd incubation bound anti Measles Virus IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti Measles Virus IgM antibodies present in the sample. Neutralization of IgG anti-measles, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.

Measles virus IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the semi-quantitative determination of IgG antibodies to Measles Virus in human plasma and sera. The product is intended mostly for the follow-up of anti Measles Virus vaccination and can also be useful for the follow up of infected individuals. Micro-plates are coated with Measles Virus native antigens derived from tissue culture of a virulent strain. In the 1st incubation, the solid phase is treated with diluted samples and anti Measles Virus IgG are captured, if present, by the antigens.After washing out all the other components of the sample, in the 2nd incubation bound anti Measles Virus IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti Measles Virus IgG antibodies present in the sample. IgG in the sample may therefore be semi quantitated in arbU/ml by means of its S/Co value and a calibration curve.

CoxB IgM – ELISA

Enzyme Immuno Assay (ELISA) for the determination  of   IgM antibodies to Coxsackievirus B (CoxB) in human plasma and sera.  For “in vitro” diagnostic use only. Coxsackievirus belongs to a group of viruses called enteroviruses and are present in two main groups, A and B. Most Coxsackievirus infections are not serious. They typically cause only mild signs and symptoms, such as fever, rash, sore throat, joint pain and headache. Symptoms usually last about a week. Coxsackievirus infection occurs most often in young children. Group A viruses are associated with aseptic meningitis, colds, acute hemorrhagic conjunctivitis and acute myocardiopathies and group B are associated with acute myocarditis and a polio-like paralysis.

CoxB IgG – ELISA

Enzyme Immuno Assay (ELISA) for the determination  of   IgG antibodies to Coxsackievirus type B (CoxB) in human plasma and sera.  For “in vitro” diagnostic use only. Coxsackievirus belongs to a group of viruses called enteroviruses in particular they are Picornaviruses.They are present in two main groups, A and B. Most Coxsackievirus infections are not serious. They typically cause only mild signs and symptoms, such as fever, rash, sore throat, joint pain and headache. Symptoms usually last about a week.

Extraction Kit for H.Pylori Ag – ELISA

H.Pylori Ag antigen STOOL EXTRACTION KIT

HP Ag – ELISA

Enzyme Immunoassay (ELISA) for the one-step qualitative/quantitative determination of Helicobacter pylori Antigen (HP Ag) in human stools. The kit may be used for the the follow-up of HP-infected patients and their pharmacological treatment. For "in vitro" diagnostic use only. Stools from patients are used as a source of sample for the determination of HP antigen. Microplates are coated with a cocktail of affinity purified mouse monoclonal antibodies directed to the most specific Helicobacter pylori antigens. In the 1st incubation, the solid phase is treated with the sample, previously extracted from stools, and simultaneously with a mixture of monoclonal antibodies to Hp, conjugated with peroxidase (HRP). After washing out all the other components of the sample, in the 2nd incubation the bound enzyme specifically present on the solid phase generates an optical signal that is proportional to the amount of H.pylori antigens present in the sample.

HP CagA IgG – ELISA

Enzyme Immunoassay for the quantitative determination of IgG antibodies to Helicobacter pylori cytotoxin associated gene A Antigen or CagA-Ag in sera/plasma. The product is intended for the follow-up of patients showing gastrointestinal pathologies referable to H.pylori infection. For "in vitro" diagnostic use only. Microplates are coated with Helicobacter pylori specific CagA-Ag synthetic antigen. In the 1st incubation, the solid phase is treated with diluted samples and anti CagA-Ag IgG are captured, if present, by the antigens.

HP CagA IgA – ELISA

Enzyme Immunoassay for the quantitative determination of IgA antibodies to Helicobacter pylori cytotoxin associated gene A Antigen or CagA-Ag in sera/plasma. The product is intended for the follow-up of patients showing gastrointestinal pathologies referable to H.pylori infection. For "in vitro" diagnostic use only. Microplates are coated with Helicobacter pylori specific CagA-Ag synthetic antigen. In the 1st incubation, the solid phase is treated with diluted samples and anti CagA-Ag IgA are captured, if present, by the antigens.

HP IgA – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgA antibodies to Helicobacter pylori in human plasma and sera. The product is intended for the follow-up of patients showing gastrointestinal pathologies referable to H.pylori infection.For "in vitro" diagnostic use only. Microplates are coated with H.pylori immunodominant antigens derived from tissue culture of a virulent strain. In the 1st incubation, the solid phase is treated with diluted samples and anti-HP IgA are captured, if present, by the antigens. After washing out all the other components of the sample, in the 2nd incubation bound anti-HP IgA are detected by the addition of anti hIgA antibody, labeled with peroxidase (HRP).

HP IgM – ELISA

Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Helicobacter pylori in human plasma and sera. For "in vitro" diagnostic use only. Microplates are coated with H.pylori immunodominant antigens derived from tissue culture of a virulent strain. In the 1st incubation, the solid phase is treated with diluted samples and anti-HP IgM are captured, if present, by the antigens.

HP IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgG antibodies to Helicobacter pylori in human plasma and sera. The product is intended for the follow-up of patients showing gastrointestinal pathologies potentially correlated to HP infection. For "in vitro" diagnostic use only. Microplates are coated with H.pylori immunodominant antigens derived from tissue culture of a virulent strain. In the 1st incubation, the solid phase is treated with diluted samples and anti-HP IgG are captured, if present, by the antigens.

Ea IgM – ELISA

Enzyme ImmunoAssay   (ELISA)  for   the   qualitative determination  of   IgM class antibodies to Epstein Barr Virus Early Antigen (Ea) in human plasma and sera. The kit is intended for the classification of the viral infective agent and the follow-up of EBV infected patients. For “in vitro” diagnostic use only.Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt’s lymphoma and nasopharyngeal carcinoma, or NPC.

Ea IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination  of   IgG antibodies to Epstein Barr Virus Early Antigen in human plasma and sera. For “in vitro” diagnostic use only. Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt’s lymphoma and nasopharyngeal carcinoma, or NPC.A member of the family Herpesviridae, it has a worldwide distribution, such that 80 to 90% of all adults have been infected.Primary infections usually occur during the first decade of life.

EBV EBNA IgM – ELISA

Enzyme ImmunoAssay   (ELISA)  for   the   qualitative determination  of   IgM class antibodies to Epstein Barr Virus Nuclear Antigen (EBNA) in human plasma and sera.The kit is intended for the classification of the viral infective agent and the follow-up of EBV infected patients.For “in vitro” diagnostic use only.Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt’s lymphoma and nasopharyngeal carcinoma, or NPC.

EBV EBNA IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgG antibodies to Epstein Barr Virus Nuclear Antigen in human plasma and sera. For "in vitro" diagnostic use only.Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt's lymphoma and nasopharyngeal carcinoma, or NPC. A member of the family Herpesviridae, it has a worldwide distribution, such that 80 to 90% of all adults have been infected. Primary infections usually occur during the first decade of life. While childhood infections are mostly asymptomatic, 50 to 70% of young adults undergoing primary EBV infections show mild to severe illness. EBV may cause a persistent, latent infection which can be reactivated under immunosoppression or in AIDS affected patients. As humoral responses to primary EBV infections are quite rapid, the level and class of antibodies raised in most cases allow classification as to whether the patient is still susceptible, has a current or recent primary infection, had a past infection or may be having reactivated EBV infection.

EBV VCA IgM – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative or qualitative determination of IgM class antibodies to Epstein Barr Virus (EBV) Capsidic Antigen in human plasma and sera with the "capture" system.  The kit is intended for the classification of the viral infective agent and the follow-up of EBV infected patients. For "in vitro" diagnostic use only. Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt's lymphoma and nasopharyngeal carcinoma, or NPC.  A member of the family Herpesviridae, it has a worldwide distribution, such that 80 to 90% of all adults have been infected. Primary infections usually occur during the first decade of life. While childhood infections are mostly asymptomatic, 50 to 70% of young adults undergoing primary EBV infections show mild to severe illness.

EBV VCA IgG – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgG antibodies to Epstein Barr Virus Capsidic Antigen in human plasma and sera. For "in vitro" diagnostic use only. Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt's lymphoma and nasopharyngeal carcinoma, or NPC.  A member of the family Herpesviridae, it has a worldwide distribution, such that 80 to 90% of all adults have been infected. Primary infections usually occur during the first decade of life. While childhood infections are mostly asymptomatic, 50 to 70% of young adults undergoing primary EBV infections show mild to severe illness. EBV may cause a persistent, latent infection which can be reactivated under immunosoppression or in AIDS affected patients.

EBV VCA IgA – ELISA

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination  of   IgA antibodies to Epstein Barr Virus Capsidic Antigen in human plasma and sera. For “in vitro” diagnostic use only. Epstein Barr Virus or EBV is the principal etiological agent of infectious mononucleosis, as well as a contributory factor in the etiology of Burkitt’s lymphoma and nasopharyngeal carcinoma, or NPC. A member of the family Herpesviridae, it has a worldwide distribution, such that 80 to 90% of all adults have been infected.Primary infections usually occur during the first decade of life.

Syphilis Ab (Version ULTRA) – ELISA

Enzyme ImmunoAssay (ELISA) for the determination of antibodies to Treponema pallidum (Tp) in human plasma and sera. The kit is for use in screening of blood units and the follow-up of Tp-infected patients. For "in vitro" diagnostic use only. Microplates are coated with purified Treponema pallidum synthetic antigens, derived from immunodominant protein of the bacterium. The solid phase is first treated with the diluted sample and captures antibodies if present. After the washing step, the specifically bound antibodies are detected with an anti-human IgG&M antibody, labeled with peroxidase (HRP). A substrate/chromogen solution is added and the intensity of the color developed by the bound enzyme is proportional to the amount of anti-Tp antibodies in the sample. Results are evaluated against a cut-off value able to discriminate Treponema pallidum antibody negative individuals from positive ones.